Human Monoclonal Antibody Cloning via Memory B Cell Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human monoclonal antibodies are inefficient and cumbersome, particularly in isolating full-length antibodies for therapeutic use against pathogens like HIV, due to limitations in hybridoma technology, EBV transformation, and phage display, which often result in unstable clones and structural restrictions.
Innovation Solution
A method involving the isolation of memory B cells from individuals exposed to specific antigens, followed by culturing and cloning to produce full-length monoclonal antibodies using eukaryotic expression vectors, allowing for the identification and expression of specific VH and VL chains to produce antibodies that bind to particular antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hybridoma methods are used to produce human monoclonal antibodies, then antibody production can be achieved, but the process is inefficient and produces unstable clones
Solution Approach 1:
The patent segments the antibody production process by separating memory B cell isolation from antibody cloning. Memory B cells are isolated and activated to differentiate into plasma cells, which then undergo single-cell RT-PCR to clone heavy and light chain variable regions separately. This segmentation allows for stable cloning of functional antibodies without the instability issues of hybridoma methods.
Solution Approach 2:
The patent uses an intermediary approach by introducing activated memory B cells as a bridge between antigen exposure and antibody production. These memory B cells are activated in vitro to differentiate into plasma cells that secrete antibodies, which are then cloned. This intermediary step avoids the need for cell fusion while maintaining antibody production capability and stability.
2Productivity
If EBV transformation is used to produce human monoclonal antibodies, then antibody production is possible, but the method is cumbersome and results in high clone loss
Solution Approach 1:
The patent extracts the essential function of EBV transformation (activating memory B cells to differentiate into antibody-secreting plasma cells) while removing the problematic aspects (genetic instability and high clone loss). This is achieved by using activated memory B cells directly for single-cell RT-PCR and cloning, eliminating the need for long-term EBV-transformed cell line maintenance.
3Adaptability or versatility
If phage display is used to screen antibodies, then screening can be performed, but structural restrictions are imposed on antibody specificities
Solution Approach 1:
Instead of screening antibody fragments displayed on phage and then attempting to reconstruct full antibodies, the patent inverts the approach by directly cloning full-length heavy and light chain variable regions from activated memory B cells using single-cell RT-PCR. This preserves the native structure and specificity of full antibodies without imposing phage display structural restrictions.
4Reliability
If humanization of murine mAbs is performed, then human antibodies can be produced, but the process is highly labor intensive
Solution Approach 1:
The patent uses self-service by directly isolating human memory B cells from human donors and cloning their native antibody genes. This eliminates the need for labor-intensive humanization processes where murine antibody genes must be grafted onto human frameworks. The method produces fully human antibodies through direct cloning of human B cell receptors.
Data Source
AI summary
The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).